Gupta, Nidhi
Waas, Bridget
Austin, Daniel
De Mazière, Ann M.
Kujala, Pekka
Stockwell, Amy D.
Li, Tianbo
Yaspan, Brian L.
Klumperman, Judith
Scales, Suzie J.
Funding for this research was provided by:
Genentech
NEMI (184.034.014)
Article History
Received: 14 July 2023
Accepted: 30 January 2024
First Online: 14 February 2024
Competing interests
: All Genentech employees (N.G., B.W., D.A., A.D.S., T.L., B.L.Y., S.J.S.) are/were salaried by Genentech (a member of the Roche group) and own stock in Roche. A.M.D.M. and P.K. were also salaried by Genentech under a long term contract with J.K.’s group, but do not own stock. S.J.S. and N.G. have filed a patent application disclosing APOLIPOPROTEIN L1-specific antibodies and method of use and the application is currently pending in the US and globally.